Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RITUXAN vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Rituximab is a chimeric monoclonal antibody that binds specifically to the CD20 antigen on pre-B and mature B-lymphocytes. Binding induces complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), leading to B-cell depletion.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Non-Hodgkin lymphoma (NHL),Chronic lymphocytic leukemia (CLL),Rheumatoid arthritis (RA),Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA),Pemphigus vulgaris,Off-label: immune thrombocytopenia, autoimmune hemolytic anemia, multiple sclerosis, systemic lupus erythematosus
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
375 mg/m2 IV weekly for 4 doses for non-Hodgkin lymphoma; 1000 mg IV on days 1 and 15 for rheumatoid arthritis; 375 mg/m2 IV weekly for 4 doses for chronic lymphocytic leukemia (in combination with fludarabine and cyclophosphamide).
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Mean terminal elimination half-life is approximately 22 days (range 6.1–52 days) after first dose, decreasing to about 6 days after fourth dose due to target-mediated clearance. Clinical context: Extended half-life allows for weekly or every-2-week dosing; half-life shortens with repeated dosing due to B-cell depletion.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Rituximab is a monoclonal antibody and is not metabolized by cytochrome P450 enzymes; it is degraded via catabolic pathways into small peptides and amino acids.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Rituximab is eliminated primarily via reticuloendothelial system metabolism and target-mediated clearance. Renal excretion is negligible (<1% of dose as intact antibody in urine). Biliary/fecal excretion is minimal. Clearance is influenced by tumor burden and CD20 expression.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Rituximab is a monoclonal antibody; specific protein binding is not characterized. Binding to Fc Rn may influence half-life. No significant binding to plasma proteins other than antigen targets.
Approximately 85-90% bound to serum albumin.
Volume of distribution at steady state (Vdss) is approximately 3.1–4.5 L (0.04–0.06 L/kg for a 70 kg patient), indicating limited extravascular distribution, primarily confined to plasma and interstitial fluid. Clinical meaning: Low Vd reflects distribution mainly in central compartment; minimal penetration into tissues. In non-Hodgkin lymphoma, Vd may be higher due to tumor binding.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Intravenous: 100% bioavailability. Not available for subcutaneous, intramuscular, or other routes; no oral formulation due to protein degradation.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
No dose adjustment required for renal impairment; not removed by hemodialysis.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
No specific guidelines for Child-Pugh; use caution in severe hepatic impairment as it has not been studied.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
Safety and efficacy not established in pediatric patients for most indications; use in pediatric nephrotic syndrome: 375 mg/m2 IV weekly for 4 doses.
Not established; safety and efficacy not determined in pediatric patients.
No specific dose adjustment; monitor for increased risk of infections and cardiac events.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
WARNING: Fatal infusion reactions, severe mucocutaneous reactions, progressive multifocal leukoencephalopathy (PML), and hepatitis B reactivation.
None.
Infusion reactions (fatal within 24 hours), tumor lysis syndrome, severe mucocutaneous reactions (e.g., Stevens-Johnson syndrome), hepatitis B reactivation (screen high-risk patients), progressive multifocal leukoencephalopathy (PML), cardiac arrhythmias, renal toxicity (in combination with chemotherapy), bowel obstruction/perforation, and vaccination limitations (live vaccines not recommended during treatment).
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Hypersensitivity to rituximab or any component of the formulation; active severe infections (e.g., hepatitis B, tuberculosis); severe immunocompromised state; caution in patients with history of cardiac disease or pulmonary insufficiency.
Hypersensitivity to AURLUMYN or any of its components.
No known food interactions. No dietary restrictions required.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
First trimester: There is a theoretical risk based on mechanism (B-cell depletion), but human data are limited. Rituximab is an Ig G1 antibody that crosses the placenta in the second and third trimesters, with highest fetal exposure in the third trimester. Second/third trimester: Cases of transient neonatal B-cell lymphopenia and cytopenias have been reported; however, no consistent pattern of major congenital malformations has been observed. Overall risk is considered low, but B-cell depletion in neonates is possible.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
Rituximab is excreted in human breast milk in very low concentrations; the milk-to-plasma ratio is unknown. Limited data suggest minimal oral bioavailability due to digestion in the infant gastrointestinal tract. The American Academy of Pediatrics considers rituximab compatible with breastfeeding, but caution is advised given the potential for immunosuppression in the infant. The half-life in breast milk is short, and exposure is likely minimal.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
No dose adjustments are recommended due to pregnancy-related pharmacokinetic changes. Data on rituximab clearance in pregnancy are insufficient to suggest dose changes. However, because of increased plasma volume and enhanced clearance of Ig G antibodies during pregnancy, theoretically the exposure may be reduced, but no specific dose modification is indicated. Dosing should follow standard protocols based on indication.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
Rituximab (RITUXAN) is a chimeric monoclonal antibody against CD20, used for B-cell malignancies and autoimmune diseases. Premedicate with acetaminophen, diphenhydramine, and a corticosteroid to reduce infusion reactions. Monitor for tumor lysis syndrome in high-tumor-burden patients. Hepatitis B reactivation can occur; screen all patients before therapy. Progressive multifocal leukoencephalopathy (PML) is a rare but fatal risk. Do not administer live vaccines during or after treatment until B-cell recovery.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
You may experience infusion reactions such as fever, chills, or rash; these are usually manageable with premedication.,Avoid live vaccines (e.g., MMR, shingles, yellow fever) during treatment and for at least 6 months after.,Report any signs of infection, including fever, cough, or painful urination, promptly.,Tell your doctor if you have a history of hepatitis B; this virus can reactivate and cause serious liver problems.,Use effective contraception during therapy and for 12 months after the last dose.,Do not drive or operate machinery if you experience dizziness or weakness after infusion.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RITUXAN vs AURLUMYN, answered by our medical review team.
RITUXAN is a Antineoplastic Agent that works by Rituximab is a chimeric monoclonal antibody that binds specifically to the CD20 antigen on pre-B and mature B-lymphocytes. Binding induces complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), leading to B-cell depletion.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RITUXAN and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RITUXAN is: 375 mg/m2 IV weekly for 4 doses for non-Hodgkin lymphoma; 1000 mg IV on days 1 and 15 for rheumatoid arthritis; 375 mg/m2 IV weekly for 4 doses for chronic lymphocytic leukemia (in combination with fludarabine and cyclophosphamide).. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RITUXAN and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RITUXAN is classified as Category C. First trimester: There is a theoretical risk based on mechanism (B-cell depletion), but human data are limited. Rituximab is an IgG1 antibody that crosses the placenta in the secon. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.